181 related articles for article (PubMed ID: 19419313)
1. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
Danese MD; Badamgarav E; Bauer DC
J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
[TBL] [Abstract][Full Text] [Related]
2. Potential clinical and economic impact of nonadherence with osteoporosis medications.
Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
4. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008.
Siris ES; Pasquale MK; Wang Y; Watts NB
J Bone Miner Res; 2011 Jan; 26(1):3-11. PubMed ID: 20662073
[TBL] [Abstract][Full Text] [Related]
5. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Rietbrock S; Olson M; van Staa TP
QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
[TBL] [Abstract][Full Text] [Related]
6. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
7. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
8. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
[TBL] [Abstract][Full Text] [Related]
9. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
11. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.
Hiligsmann M; Rabenda V; Bruyère O; Reginster JY
Health Policy; 2010 Jul; 96(2):170-7. PubMed ID: 20153543
[TBL] [Abstract][Full Text] [Related]
12. Compliance with drug therapies for the treatment and prevention of osteoporosis.
McCombs JS; Thiebaud P; McLaughlin-Miley C; Shi J
Maturitas; 2004 Jul; 48(3):271-87. PubMed ID: 15207894
[TBL] [Abstract][Full Text] [Related]
13. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.
Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL
Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121
[TBL] [Abstract][Full Text] [Related]
15. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
Zambon A; Baio G; Mazzaglia G; Merlino L; Corrao G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
[TBL] [Abstract][Full Text] [Related]
16. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
18. Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein S
Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
[TBL] [Abstract][Full Text] [Related]
19. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
20. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
